Bristol Total Current Liabilities vs Total Liab Analysis
BMY Stock | USD 43.99 0.29 0.66% |
Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Total Current Liabilities and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Total Current Liabilities vs Total Liab
Total Current Liabilities vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Total Current Liabilities account and Total Liab. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Bristol Myers' Total Current Liabilities and Total Liab is 0.94. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Liab in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Total Current Liabilities and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Bristol Myers Squibb are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Current Liabilities i.e., Bristol Myers' Total Current Liabilities and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.94 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Current Liabilities
Total Current Liabilities is an item on Bristol Myers balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bristol Myers Squibb are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 36.4B | 36.0B | 34.3B | 36.0B | Total Revenue | 46.4B | 46.2B | 45.0B | 47.3B |
Bristol Myers fundamental ratios Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Short Long Term Debt Total | 47.5B | 51.7B | 45.6B | 40.7B | 41.5B | 43.5B | |
Other Current Liab | 7.9B | 10.2B | 10.1B | 13.1B | 11.5B | 12.1B | |
Total Current Liabilities | 18.3B | 19.1B | 21.9B | 21.9B | 22.3B | 23.4B | |
Total Stockholder Equity | 51.6B | 37.8B | 35.9B | 31.1B | 29.4B | 15.0B | |
Property Plant And Equipment Net | 6.3B | 6.7B | 7.0B | 7.5B | 8.0B | 5.2B | |
Net Debt | 35.2B | 37.1B | 31.6B | 31.6B | 30B | 31.5B | |
Retained Earnings | 34.5B | 21.3B | 23.8B | 25.5B | 28.8B | 22.0B | |
Cash | 12.3B | 14.5B | 14.0B | 9.1B | 11.5B | 12.0B | |
Non Current Assets Total | 100.6B | 88.3B | 76.1B | 69.5B | 63.4B | 66.6B | |
Non Currrent Assets Other | 6.6B | 2.1B | 1.7B | 1.0B | 1.9B | 2.0B | |
Cash And Short Term Investments | 12.3B | 14.5B | 14.0B | 9.1B | 12.3B | 12.9B | |
Net Receivables | 7.7B | 8.5B | 12.5B | 13.9B | 15.3B | 16.0B | |
Good Will | 22.5B | 20.5B | 20.5B | 21.1B | 21.2B | 22.2B | |
Common Stock Shares Outstanding | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 1.6B | |
Liabilities And Stockholders Equity | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Non Current Liabilities Total | 59.9B | 61.5B | 51.4B | 43.8B | 43.4B | 45.6B | |
Inventory | 4.3B | 2.1B | 2.1B | 2.3B | 2.7B | 1.9B | |
Other Current Assets | 2.0B | 1.4B | 1.3B | 1.6B | 1.5B | 1.8B | |
Other Stockholder Equity | 18.4B | 18.1B | 13.1B | 6.5B | 1.9B | 2.0B | |
Total Liab | 78.2B | 80.6B | 73.3B | 65.7B | 65.7B | 69.0B | |
Property Plant And Equipment Gross | 6.3B | 5.9B | 11.0B | 11.6B | 12.8B | 13.5B | |
Total Current Assets | 29.4B | 30.2B | 33.3B | 27.3B | 31.8B | 33.4B | |
Accumulated Other Comprehensive Income | (1.5B) | (1.8B) | (1.3B) | (1.3B) | (1.5B) | (1.6B) | |
Short Term Debt | 3.5B | 2.5B | 5.1B | 4.4B | 3.3B | 3.4B | |
Intangible Assets | 64.0B | 53.2B | 42.8B | 36.4B | 27.5B | 28.9B | |
Accounts Payable | 2.4B | 2.7B | 2.9B | 3.0B | 3.3B | 1.9B | |
Short Term Investments | 3.0B | 1.3B | 3.2B | 130M | 816M | 775.2M | |
Other Liab | 15.9B | 12.3B | 11.0B | 7.4B | 8.5B | 4.9B | |
Other Assets | 4.8B | 7.3B | 3.3B | 2.9B | 3.3B | 3.3B | |
Long Term Debt | 43.4B | 48.3B | 39.6B | 35.1B | 36.7B | 38.5B | |
Treasury Stock | (25.4B) | (26.2B) | (31.3B) | (38.6B) | (43.8B) | (41.6B) | |
Property Plant Equipment | 6.3B | 5.9B | 6.0B | 6.3B | 7.2B | 5.8B | |
Current Deferred Revenue | 4.5B | 3.6B | 3.7B | 1.3B | 4.2B | 4.4B | |
Net Tangible Assets | (34.9B) | (36.0B) | (28.2B) | (25.9B) | (23.4B) | (22.2B) | |
Noncontrolling Interest In Consolidated Entity | 96M | 100M | 60M | 57M | 55M | 74.7M |
Bristol Myers Investors Sentiment
The influence of Bristol Myers' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bristol. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Bristol Myers' public news can be used to forecast risks associated with an investment in Bristol. The trend in average sentiment can be used to explain how an investor holding Bristol can time the market purely based on public headlines and social activities around Bristol Myers Squibb. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bristol Myers' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bristol Myers' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bristol Myers' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bristol Myers.
Bristol Myers Implied Volatility | 31.57 |
Bristol Myers' implied volatility exposes the market's sentiment of Bristol Myers Squibb stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Bristol Myers' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Bristol Myers stock will not fluctuate a lot when Bristol Myers' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myers in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myers' short interest history, or implied volatility extrapolated from Bristol Myers options trading.
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
0.65 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Bristol Stock
0.41 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.34 | Earnings Share (3.10) | Revenue Per Share 22.212 | Quarterly Revenue Growth 0.047 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.